Fresenius Medical Care AG (NYSE:FMS) shares traded up 1.1% during mid-day trading on Tuesday . The stock traded as high as $46.67 and last traded at $46.15, with a volume of 133,199 shares. The stock had previously closed at $45.65.

A number of research analysts have weighed in on FMS shares. Jefferies Group raised shares of Fresenius Medical Care AG from an “underperform” rating to a “hold” rating in a report on Friday, July 8th. Royal Bank Of Canada reaffirmed a “hold” rating on shares of Fresenius Medical Care AG in a report on Tuesday, May 24th. Robert W. Baird reaffirmed a “hold” rating on shares of Fresenius Medical Care AG in a report on Monday, May 16th. DZ Bank AG reaffirmed a “sell” rating on shares of Fresenius Medical Care AG in a report on Tuesday, May 10th. Finally, Zacks Investment Research raised shares of Fresenius Medical Care AG from a “sell” rating to a “hold” rating in a report on Wednesday, May 4th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and six have assigned a buy rating to the company’s stock. Fresenius Medical Care AG has a consensus rating of “Hold” and a consensus target price of $42.50.

The stock’s 50-day moving average is $43.21 and its 200 day moving average is $43.01. The stock has a market capitalization of $28.20 billion and a P/E ratio of 26.87.

Fresenius Medical Care AG (NYSE:FMS) last announced its quarterly earnings data on Tuesday, May 3rd. The company reported $0.75 EPS for the quarter, topping the Zacks’ consensus estimate of $0.42 by $0.33. The firm had revenue of $4.21 billion for the quarter, compared to analysts’ expectations of $4.25 billion. During the same quarter in the previous year, the company posted $0.69 EPS. The firm’s quarterly revenue was up 6.2% compared to the same quarter last year. On average, analysts expect that Fresenius Medical Care AG will post $2.03 EPS for the current year.

A number of institutional investors have recently made changes to their positions in the company. US Bancorp DE increased its position in shares of Fresenius Medical Care AG by 4.0% in the fourth quarter. US Bancorp DE now owns 274,935 shares of the company’s stock worth $11,503,000 after buying an additional 10,479 shares during the last quarter. Comerica Bank increased its position in shares of Fresenius Medical Care AG by 5.4% in the fourth quarter. Comerica Bank now owns 35,387 shares of the company’s stock worth $1,486,000 after buying an additional 1,798 shares during the last quarter. WBI Investments Inc. purchased a new position in shares of Fresenius Medical Care AG during the fourth quarter worth approximately $2,249,000. Bank of Montreal Can increased its position in shares of Fresenius Medical Care AG by 60.0% in the fourth quarter. Bank of Montreal Can now owns 56,700 shares of the company’s stock worth $2,373,000 after buying an additional 21,264 shares during the last quarter. Finally, Morgan Stanley increased its position in shares of Fresenius Medical Care AG by 20.5% in the fourth quarter. Morgan Stanley now owns 685,338 shares of the company’s stock worth $28,675,000 after buying an additional 116,653 shares during the last quarter.

Fresenius Medical Care AG & Co KGaA (FMC AG & CO. KGAA) is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end stage renal disease (ESRD), as well as other healthcare services. The Company operates through four segments: North America, Europe, Middle East, Africa (EMEA), Asia-Pacific and Latin America.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.